Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 AI cyclic peptide drug discovery with Bristol Myers Squibb collaboration May 2024; $4.15M Khosla/Uncork/Feld-backed using ML+quantum computing for peptide optimization competing with Relay Therapeutics for pharma licensing.
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
NYSE-listed (WRBY) DTC eyewear brand with $669M revenue and 240+ stores; vertical integration enabling $95-195 glasses competing with LensCrafters while pursuing profitability path after 2021 IPO.
Warby Parker is a New York-based direct-to-consumer eyewear company that disrupted the traditional optical retail industry by designing, manufacturing, and selling prescription glasses and sunglasses directly to consumers at $95-$195 price points — compared to $300-500 at traditional optical retailers that added brand markups, optician markups, and optical shop overhead. Listed on NYSE (NYSE: WRBY), Warby Parker generated $669 million in net revenue in fiscal year 2023 and operates 240+ retail stores across the US and Canada alongside its e-commerce and home try-on program.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.